



## EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024

May 02, 2024

*Company to host conference call and webcast on Thursday, May 16<sup>th</sup> at 8:30am EDT*

LYON, France, May 2, 2024 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2024, before the markets open on Thursday, May 16<sup>th</sup>, 2024.

An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.

### Call Details:

Date: Thursday, May 16<sup>th</sup>  
Time: 8:30 am EDT  
Domestic: 1-877-451-6152  
International: 1-201-389-0879  
Passcode: 13745791  
CallMe™ [LINK](#) (active 15 minutes prior to conference call)  
Webcast: [https://viaid.webcasts.com/starthere.jsp?ei=1665376&tp\\_key=00daa24457](https://viaid.webcasts.com/starthere.jsp?ei=1665376&tp_key=00daa24457)

### About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market. EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit <http://www.edap-tms.com>, [us.hifu-prostate.com](http://us.hifu-prostate.com) and [www.focalone.com](http://www.focalone.com).

### Company Contact

Blandine Confort  
Investor Relations / Legal Affairs  
EDAP TMS SA  
+33 4 72 15 31 50  
[bconfort@edap-tms.com](mailto:bconfort@edap-tms.com)

### Investor Contact

John Fraunces  
LifeSci Advisors, LLC  
(917) 355-2395  
[jfraunces@lifesciadvisors.com](mailto:jfraunces@lifesciadvisors.com)